This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): rimonabant, SR 141716, Acomplia
Description: The binding of endogenous ligands, such as anadamide, to cannabinoid CB1 receptors in the brain increases appetite and other cravings such as smoking. Acomplia works by blocking endogenous ligand binding to neuronal CB1 receptors.
Deal Structure: Sanofi-Aventis announced in April 2006 that it agreed with Astellas Pharma Inc. to accelerate the transfer of all rights to Acomplia in Japan from a joint-venture company held by the two groups, to Sanofi-Aventis.
Pink Sheet Sanofi-Aventis Zimulti (correction)
Pink Sheet ‘Complete Response’ Letters
Additional information available to subscribers only: